港股早評:三大指數高開 科技股普升 利好來襲三胎概念股強勢
隔夜美股三大指數收升,中概指數大升超4%。港股今日高開,恒指升0.63%,國指升0.76%,恒生科技指數升1.63%。盤面上,大型科技股全線上升,美團升2.16%,京東、百度、快手升約2%,網易、小米升1.6%,阿里巴巴、騰訊均上升;生育支持系列措施來了,母嬰及輔助生殖產業有望受益,輔助生殖龍頭錦欣生殖大升近15%,三胎概念股等強勢,中國飛鶴升6.8%;行業存在超跌反彈機遇,光伏股再度活躍,信義光能大升10%;汽車股、生物醫藥股、直播概念股、餐飲股、鋰電池股普遍上升。另一方面,花旗下調油價目標,石油股部分延續跌勢,中石化跌超3%,黃金股、家電股、海運股、內險股個別走低。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.